In 2010, Dixon et al. showed higher risk of death with a higher prevalence of ILD in the anti-TNFα group with respect to synthetic DMARDs (2.8% versus 1.9%  P = 0.006) [26]. This evidence concerns the gene TNF and interstitial lung disease.